Proteomics-Based Strategy to Identify Biomarkers and Pharmacological Targets in Leukemias with t(4;11) Translocations
- 18 August 2006
- journal article
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 5 (10), 2743-2753
- https://doi.org/10.1021/pr060235v
Abstract
Translocations and other aberrations involving the MLL (mixed lineage leukemia) gene result in aggressive forms of leukemias. Heterogeneity in partner genes, in chromosomal breakpoints, in MLL itself, and in the different partner genes results in heterogeneous fusion transcripts that can be alternatively spliced, which complicates deciphering a unifying mechanism of leukemogenesis. However, recent microarray studies completed with clinical leukemia specimens have uncovered several distinct mRNA signatures within MLL leukemia that differ from other types of leukemia. A global proteomics strategy using MV4-11 and RS4:11 cells in culture was employed to investigate possible protein signatures common to different MLL leukemias and to identify disease biomarkers and protein targets for pharmacological intervention. Initial proteomics screening experiments with two-dimensional differential in-gel electrophoresis revealed heat shock protein 90 alpha (HSP90α) as a potential target for pharmacological inhibition and nucleoside diphosphate kinase (nm23) as a biomarker for measuring treatment efficacy. Using a modified stable isotope labeling of amino acids in cell culture (SILAC) approach, coupled with two-dimensional liquid chromatography tandem mass spectrometry (2D-LC−MS/MS), changes in abundance for over 500 proteins were measured. In addition, decreased expression of the novel biomarker nm23 was observed during HSP90 inhibition with 17-allylamino-17-demethoxygeldanamycin (17-AAG) in the MV4-11 cell line. The present study validates the use of a global proteomics strategy to uncover novel biomarkers and pharmacological targets for leukemias with MLL translocations. Additionally, several proteins were found to be expressed in concordance with microarray studies of mRNA expression in specimens from patients showing the value in comparing mRNA transcript and proteomic profiles. This work represents one of the most comprehensive proteomics screens of MLL leukemias that have been conducted to date. Keywords: MLL • chromosomal breakpoints • leukemia • proteomics • MS/MS • differential in-gel electrophoresis • heat shock protein 90 • SILAC • nucleoside diphosphate kinaseKeywords
This publication has 30 references indexed in Scilit:
- New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genesLeukemia, 2005
- When epigenetics kills: MLL fusion proteins in leukemiaHematological Oncology, 2005
- A novel experimental design for comparative two‐dimensional gel analysis: Two‐dimensional difference gel electrophoresis incorporating a pooled internal standardProteomics, 2003
- MLL Targets SET Domain Methyltransferase Activity to Hox Gene PromotersMolecular Cell, 2002
- Human Genome and Diseases:¶Double-strand breaks and translocations in cancerCellular and Molecular Life Sciences, 2002
- MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemiaNature Genetics, 2001
- Molecular mechanisms of leukemogenesis mediated by MLL fusion proteinsOncogene, 2001
- Leukemias related to treatment with DNA topoisomerase II inhibitors*Medical and Pediatric Oncology, 2001
- The amino terminus targets the mixed lineage leukemia (MLL) protein to the nucleolus, nuclear matrix and mitotic chromosomal scaffoldsLeukemia, 2000
- Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs.Proceedings of the National Academy of Sciences of the United States of America, 1993